Biologics CDMO market seen topping $50 billion by 2030

The Business Research Company projects the global biologics contract development and manufacturing organization market will reach $50.29 billion by 2030, driven by outsourcing demand, complex manufacturing needs and biologics growth across therapeutic areas. Asia-Pacific is forecast to become the largest region, while the U.S. remains the biggest single-country market.

Why it matters: - The biologics CDMO market is set to become a roughly $50 billion segment by 2030, giving contract manufacturers a bigger role in biologics development and production. - The market is projected to account for about 10% of the broader contract development and manufacturing market and nearly 2% of the total pharmaceuticals industry value by 2030. - Growth signals more outsourcing from drugmakers that want specialized capacity for complex biologics, biosimilars and advanced therapies.

What happened: - The Business Research Company released its Biologics CDMO Market Report 2026 – Market Size, Trends, and Global Forecast 2026-2035 on June 21, 2026. - The report says the global biologics contract development and manufacturing organization market will reach $50.29 billion by 2030. - The report pegs the market’s expected CAGR at 15.5%. - The report also lists a 15% expected CAGR leading up to 2030. - The company offers a free sample of the report. - The full report is available here.

The details: - Asia-Pacific is forecast to be the largest region in 2030, with a market value of $18 billion. - Asia-Pacific is expected to grow from $8 billion in 2025 at an 18% CAGR. - The report ties that growth to expanding biologics production capacity, more outsourcing of biologic drug development, lower manufacturing costs, more skilled bioprocessing talent, faster biosimilar and novel biologics approvals, and investment in fermentation and cell culture infrastructure. - The U.S. is projected to be the largest country market in 2030, at $14 billion. - The U.S. market is expected to grow from $7 billion in 2025 at a 14% CAGR. - U.S. growth is linked to outsourcing demand from large pharma and biotech startups, rising monoclonal antibodies, cell and gene therapies, mRNA vaccines, and more spending on continuous bioprocessing and single-use technologies. - By cell type, mammalian production is expected to be the largest segment in 2030, at 64% of the market or $32 billion. - The mammalian segment is forecast to benefit from demand for monoclonal antibodies and recombinant proteins, compatibility with human-like post-translational modifications, and larger cell-culture capacity. - The market is segmented by product type into biologics and biosimilars. - The market is segmented by service type into drug substance manufacturing, drug product fill-finish manufacturing, process development, and analytical and quality testing services. - The mammalian and non-mammalian segments are expected to contribute more than $26 billion in combined market value by 2030. - The mammalian segment is projected to grow by $17 billion from 2025 to 2030. - The non-mammalian segment is projected to grow by $9 billion over the same period.

Between the lines: - The report points to a market shaped less by one product category and more by the economics of outsourcing specialized manufacturing. - Big projected gains in Asia-Pacific suggest manufacturing capacity and policy support there are becoming as important as drug discovery pipelines. - The emphasis on mammalian systems shows that high-value, complex biologics remain the center of near-term CDMO demand. - The report also highlights a broader industry shift toward flexible, high-capacity, compliance-ready manufacturing infrastructure.

What's next: - The report expects demand to keep rising as biologics pipelines expand across vaccines, recombinant proteins and gene therapies. - CDMOs are likely to keep adding capacity in large-scale fermentation, cell culture, continuous processing and single-use systems. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated trend analysis. - The company says its research platform spans more than 30,000 reports across 27 industries and 60 geographies, supported by 1,500,000 datasets and interviews with industry leaders.

The bottom line: - The biologics CDMO market is moving from niche support function to core infrastructure for the biologics industry, with Asia-Pacific and mammalian manufacturing set to capture the biggest gains.